Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 2398609)

1.

Pharmacists' and physicians' perception and exposure to drug promotion: A Saudi study.

Zaki NM.

Saudi Pharm J. 2014 Dec;22(6):528-36. doi: 10.1016/j.jsps.2014.02.008. Epub 2014 Mar 6.

2.

Interactions between medical residents and drug companies: a national survey after the Mediator® affair.

Montastruc F, Moulis G, Palmaro A, Gardette V, Durrieu G, Montastruc JL.

PLoS One. 2014 Oct 3;9(10):e104828. doi: 10.1371/journal.pone.0104828. eCollection 2014.

3.

What do Libyan doctors perceive as the benefits, ethical issues and influences of their interactions with pharmaceutical company representatives?

Alssageer MA, Kowalski SR.

Pan Afr Med J. 2013 Apr 6;14:132. doi: 10.11604/pamj.2013.14.132.2598. Print 2013.

4.

Japanese practicing physicians' relationships with pharmaceutical representatives: a national survey.

Saito S, Mukohara K, Bito S.

PLoS One. 2010 Aug 13;5(8):e12193. doi: 10.1371/journal.pone.0012193.

5.

Prescribers and pharmaceutical representatives: why are we still meeting?

Fischer MA, Keough ME, Baril JL, Saccoccio L, Mazor KM, Ladd E, Von Worley A, Gurwitz JH.

J Gen Intern Med. 2009 Jul;24(7):795-801. doi: 10.1007/s11606-009-0989-6. Epub 2009 May 8.

6.

Characteristics and impact of drug detailing for gabapentin.

Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA.

PLoS Med. 2007 Apr;4(4):e134.

7.

Physicians and drug representatives: exploring the dynamics of the relationship.

Chimonas S, Brennan TA, Rothman DJ.

J Gen Intern Med. 2007 Feb;22(2):184-90.

8.

Interactions of doctors with the pharmaceutical industry.

Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J.

J Med Ethics. 2006 Oct;32(10):559-63.

9.

Interactions between pharmaceutical representatives and doctors in training. A thematic review.

Zipkin DA, Steinman MA.

J Gen Intern Med. 2005 Aug;20(8):777-86. Review.

11.

Pharmaceutical advertising revenue and physician organizations: how much is too much?

Glassman PA, Hunter-Hayes J, Nakamura T.

West J Med. 1999 Oct;171(4):234-8.

12.

Accepting commercial sponsorship. Disclosure helps--but is not a panacea.

Bero LA.

BMJ. 1999 Sep 11;319(7211):653-4. No abstract available.

13.
15.
16.

Attitudes of general practitioners in New Zealand to pharmaceutical representatives.

Thomson AN, Craig BJ, Barham PM.

Br J Gen Pract. 1994 May;44(382):220-3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk